Uncovering Rare Genetic Factors with Multiplex Germline Testing
Pauline Funchain, MD,
discusses the use of multiplex germline testing for rare diseases and cancers and explains the benefits of uncovering genetic factors.
CALR-Mutant Myeloproliferative Neoplasms Induced by MPL Downstream Activation
Study performed by researchers at Juntendo University reveals molecular mechanisms that trigger CALR-mutant
myeloproliferative neoplasms (MPNs).
sNDA Submitted to FDA for Venetoclax in AML Patients Ineligible for Intensive Chemotherapy
AbbVie has submitted a supplemental new drug application to the FDA for venetoclax to be used in combination with HMA or LDAC for the treatment of AML patients who are ineligible for intensive chemotherapy.
Ibrutinib Combination Therapy for DLBCL Falls Short of Phase 3 Primary Endpoint
Results from a phase 3 clinical trial evaluating an ibrutnib combination with a chemotherapy regimen for the treatment of diffuse large B-cell lymphoma fails to meet primary endpoint.
FDA Grants sBLA to Advanced Hepatocellular Carcinoma
The FDA has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for pembrolizumab (KEYTRUDA) for the treatment of advanced hepatocellular carcinoma (HCC).
The Pivotal Role of Clinical Trials in Lymphoma Treatments
Owen A. O’Connor, MD, PhD, outlines the importance of clinical trials and reviewed strides made in lymphoma treatments.
Indoximod Plus Radio-Immunotherapy Might Help Pediatric Patients With DIPG
Updated phase 1 data assessing indoximod plus front-line radiation and maintenance chemotherapy for the treatment of pediatric patients with DIPG proves promising.
Decoding Rhabdomyosarcoma with the iExCN Algorithm
Researchers from UT Southwestern Medical Center have identified 29 genes thought to contribute to rhabdomyosarcoma using the iExCN algorithm, a novel hybrid technology.
Teleconsulting: Bridging the Gap for Rare Cancer Patients
Teleconsulting technology through the European Network for Rare Adult Solid Cancer (EURACAN) will better help rare adult solid cancer patients achieve appropriate diagnoses and treatments.
JAK Inhibitors to Treat Myelofibrosis Could Lead to Development of Lymphomas
Researchers find that JAK inhibitors used to treat myelofibrosis may actually lead to the development of aggressive lymphomas.
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.